CLINICAL TRIALS PROFILE FOR BETA CAROTENE
✉ Email this page to a colleague
505(b)(2) Clinical Trials for Beta Carotene
| Trial Type | Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|---|
| OTC | NCT02131194 ↗ | The Post-Vitrectomy Lenstatin™ Study | Completed | Lenstatin LLC | N/A | 2014-06-01 | To determine the efficacy of Lenstatin™, an over-the-counter nutritional supplement, in inhibiting the progression of nuclear cataract in eyes after pars plana vitrectomy. |
| >Trial Type | >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
All Clinical Trials for Beta Carotene
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00000152 ↗ | Randomized Trial of Beta-Carotene and Macular Degeneration | Unknown status | National Eye Institute (NEI) | Phase 3 | 1982-04-01 | To determine whether 50 mg of beta-carotene taken every other day reduces the risk of developing age-related macular degeneration (AMD) among male U.S. physicians who were aged 40 to 84 in 1982. To investigate the possible relationship of AMD with other antioxidants, including selenium and vitamins A, C, and E. To identify potential risk factors for development of AMD. Possible risk factors include height, systemic hypertension, cardiovascular disease, blood cholesterol, cigarette smoking, iris and skin color, sunlight exposure, body mass index, diabetes, and alcohol intake. |
| NCT00000157 ↗ | Randomized Trial of Aspirin and Cataracts in U.S. Physicians | Terminated | National Eye Institute (NEI) | Phase 3 | 1982-04-01 | To determine whether 325 mg of aspirin taken on -alternate days reduces the risk of developing cataract among male U.S. physicians who were aged 40 to 84 in 1982. To identify potential risk factors for cataract development, such as age, blood pressure, blood cholesterol, height, diabetes, medication use, and history of previous eye trauma or surgery. |
| NCT00000161 ↗ | Randomized Trials of Vitamin Supplements and Eye Disease | Unknown status | National Eye Institute (NEI) | Phase 3 | 1993-08-01 | To determine whether vitamin E supplementation reduces the risk of cataract and age-related macular degeneration (AMD) in women. To determine whether vitamin C supplementation reduces the risk of cataract and AMD in women. To determine whether beta-carotene supplementation reduces the risk of cataract and AMD in women. To determine whether alternate day, low-dose aspirin reduces the risk of cataract and AMD in women. To identify potential risk factors for cataract and AMD including cigarette smoking, alcohol intake, blood pressure, blood cholesterol, cardiovascular disease, height, body mass index, and diabetes. |
| NCT00000500 ↗ | Physicians' Health Study | Completed | National Heart, Lung, and Blood Institute (NHLBI) | Phase 3 | 1981-09-01 | To assess the effect on cardiovascular mortality of alternate-day consumption of 325 milligrams of aspirin and, secondarily, the effect on cancer incidence of alternate-day consumption of 50 milligrams of beta-carotene. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Beta Carotene
Condition Name
Clinical Trial Locations for Beta Carotene
Trials by Country
Clinical Trial Progress for Beta Carotene
Clinical Trial Phase
Clinical Trial Sponsors for Beta Carotene
Sponsor Name
